Extension usage examples:
Here's how our browser extension sees the article:
Article summary:
1. A phase 3 trial of neoadjuvant and adjuvant therapy with pembrolizumab in patients with previously untreated stage II or III triple-negative breast cancer showed that the addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response.
2. The primary end points were pathological complete response and event-free survival, which was defined as the time from randomization to the date of disease progression that precluded definitive surgery, local or distant recurrence, occurrence of a second primary cancer, or death from any cause.
3. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab after surgery resulted in significantly longer event-free survival than neoadjuvant chemotherapy alone.
Article analysis:
The article is generally reliable and trustworthy, as it is based on a phase 3 trial conducted by an experienced team of researchers and clinicians. The article provides detailed information about the study design, methods used, results obtained, and conclusions drawn. Furthermore, the authors provide a comprehensive list of references for further reading on the topic.
However, there are some potential biases that should be noted. First, the study was funded by Merck Sharp & Dohme (MSD), which could lead to bias in favor of MSD’s product (pembrolizumab). Second, while the authors provide a comprehensive list of references for further reading on the topic, they do not explore any counterarguments or alternative treatments that may be available for early triple-negative breast cancer. Finally, while the authors note possible risks associated with pembrolizumab treatment (such as adverse events), they do not present both sides equally; instead they focus primarily on its benefits without providing an equal amount of information about potential risks associated with its use.